Medicines development and regulation in Africa
Journal Title: Journal of Medicines Development Sciences - Year 2015, Vol 1, Issue 2
Abstract
Africa is one of the world’s fastest-growing economic regions, with a rise in its pharmaceutical industry value from $4.7 billion in 2003 to $20.8 billion in 2013. Multinational pharmaceutical companies are becoming more active in drug production and clinical trials across Africa, and there is an increase in the number of local companies engaged in medicines development and marketing. Such expansion of the local pharmaceutical industry requires trained pharmaceutical specialists to support it. The current situation and future requirements for local medicines development, regulation, education and training needs are discussed.
Authors and Affiliations
Bernd Rosenkranz, Michael Reid and Elizabeth Allen
Keywords
Related Articles
- EP ID EP679251
- DOI -
- Views 208
- Downloads 0
EUPATI: Collaboration between patients, academia and industry to champion the informed patient in the research and development of medicines
The value of collaborations and partnerships between different stakeholders to achieve optimum outcomes in the medicines research and development process is being recognised. Historically, there has been a lack of collab...
Role of the P2Y6 receptor of UDP in the modulation of murine dendritic cell functions and Th1 polarisation of the immune response
Numerous studies have demonstrated the role of uridine diphosphate (UDP) and its P2Y6 receptor in the inflammatory reaction and innate immunity. However, the importance of the P2Y6 receptor in the adaptive immune respons...
A systems approach to enhance clinical research and medicines development
The biopharmaceutical industry has traditionally been the key link between basic biomedical discovery and novel medicines. Today, the industry faces numerous challenges including the broad agreement that the current clin...
HDL therapies — past, present and future
For a number of years, high-density lipoprotein (HDL) has been recognized to have an athero-protective role by promoting reverse lipid transport, a process facilitating the cholesterol efflux from atherosclerotic plaques...
The Predictive Safety Testing Consortium: safety biomarkers, collaboration, and qualification
The Predictive Safety Testing Consortium (PSTC) is one of nine consortia comprising the Critical Path Institute (C-Path), a non-profit organisation launched in 2005 and dedicated to playing the role of a catalyst in the...